EVH vs OSCR vs CLOV vs ALHC

For growth investors, Alignment Healthcare, Inc.

(ALHC) is the stronger pick with 46. 1% revenue growth year-over-year, versus -26. 6% for Evolent Health, Inc. (EVH). Analysts rate Evolent Health, Inc. (EVH) a "Buy" — based on 29 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Oscar Health, Inc.

(OSCR) delivered a total return of -7. 3%, compared to -78. 4% for Evolent Health, Inc. (EVH). Over 10 years, the gap is even starker: ALHC returned +5. 4% versus CLOV's -72. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alignment Healthcare, Inc.

(ALHC) is the lower-risk stock at 0. 75β versus Oscar Health, Inc. 's 1. 84β — meaning OSCR is approximately 145% more volatile than ALHC relative to the S&P 500. On balance sheet safety, Oscar Health, Inc. (OSCR) carries a lower debt/equity ratio of 44% versus 2% for Evolent Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alignment Healthcare, Inc.

(ALHC) is pulling ahead at 46. 1% versus -26. 6% for Evolent Health, Inc. (EVH). On earnings-per-share growth, the picture is similar: Alignment Healthcare, Inc. grew EPS 99. 4% year-over-year, compared to -1865. 9% for Oscar Health, Inc.. Over a 3-year CAGR, OSCR leads at 41. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alignment Healthcare, Inc.

(ALHC) is the more profitable company, earning -0. 0% net margin versus -28. 5% for Evolent Health, Inc. — meaning it keeps -0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALHC leads at 0. 4% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — CLOV leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Evolent Health, Inc.

(EVH) trades at 31. 2x forward P/E versus 140. 9x for Alignment Healthcare, Inc. — 109. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for EVH: 49. 1% to $6. 38.

In this comparison, EVH (2.

3% yield) pays a dividend. OSCR, CLOV, ALHC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Evolent Health, Inc.

(EVH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 21), 2. 3% yield). Oscar Health, Inc. (OSCR) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EVH: -63. 6%, OSCR: -40. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EVH is a small-cap quality compounder stock; OSCR is a small-cap high-growth stock; CLOV is a small-cap high-growth stock; ALHC is a small-cap high-growth stock. EVH pays a dividend while OSCR, CLOV, ALHC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.